UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 21, 2004
Callisto Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 333-63474 13-3894575
(State or other jurisdiction (Commission IRS Employer
of incorporation or organization) File Number) Identification No.)
420 Lexington Avenue, Suite 2500
New York, New York 10170
(Address of principal executive offices)
Registrant's telephone number, including area code: (212) 297-0010
(Former name or former address, if changed since last report)
Item 5 Other Events and Required FD Disclosure.
Pursuant to Rule 135c of the Securities Act of 1933, as amended (the
"Securities Act"), the full text of a press release issued by Callisto
Pharmaceuticals, Inc. (the "Company") on January 21, 2004 is attached as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
On January 21, 2004, the Company announced that it completed a private
placement of 3,905,432 shares of its common stock at an issue price of $1.50 per
share for aggregate proceeds of $5,858,147.66. The Company is obligated to file
a registration statement with the Securities and Exchange Commission within 90
days of the final closing registering the resale of the shares of common stock
sold in the private placement. Failure to meet this deadline could result in the
Company being obligated to pay certain liquidated damages to the investors. The
Company paid an aggregate $545,315 to various selling agents. In addition, the
Company issued 31,467 shares of common stock and an aggregate 363,544 warrants
to purchase common stock to such selling agents. The warrants are immediately
exercisable at $1.90 per share and will expire five years after issuance.
The securities described herein have not been registered under the
Securities Act. Accordingly, these securities may not be offered or sold in the
United States, except pursuant to the effectiveness of a registration statement
or an applicable exemption from the registration requirements of the Securities
Act. The foregoing summary description of the terms of the securities issued by
the Company is qualified in its entirety by reference to the definitive
transaction documents, copies of which are attached as exhibits to this Current
Report on Form 8-K.
Item 7 Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
Exhibit Number Description
4.1 Form of Warrant to purchase shares of Common
Stock issued in connection with the sale of
the Common Stock
10.1 Form of Registration Rights Agreement, dated
as of January 21, 2004 by and among the
Registrant and the purchasers set forth on
the signature page thereto.
99.1 Press Release dated January 21, 2004.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereto duly authorized.
Dated: January 28, 2004
CALLISTO PHARMACEUTICALS, INC.
By: /s/ Gary S. Jacob
-----------------------------------
Gary S. Jacob, Ph.D.
Chief Executive Officer
3